Precision Biologics announces that a Phase 2 Clinical Trial, combining NEO-201 with Pembrolizumab, is recruiting...
Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen summit, Clinical...
Dr. Philip M. Arlen gives scientific presentation at the Festival of Biologics, World Immunotherapy Congress,...
Dr. Philip M. Arlen gives scientific presentation at World Vaccine & Immunotherapy Congress West Coast...
Dr. Philip M. Arlen gives scientific presentation in 5th Annual Neoantigen Based Therapies Summit, entitled...
Dr. Philip M Arlen, MD, President and CEO is Presenting the Following Talk at the...
NIH Intramural Research Program (IRP) highlights Precision Biologics NEO-201 monoclonal antibody.
Precision Biologics in conjunction with our research collaborators at the National Cancer Institute (NCI) have...
Precision Biologics along with our collaborators at the National Cancer Institute present research data using...
Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...